Safety pharmacology: concepts and importance MCQs With Answer

Introduction

Safety pharmacology is a critical discipline that assesses potential undesirable pharmacodynamic effects of new chemical entities on vital organ systems. For M. Pharm students, mastering safety pharmacology concepts—such as the core battery (cardiovascular, respiratory, central nervous system), ICH guidance (S7A/S7B), in vitro hERG testing, telemetry, and margin-of-safety calculations—is essential for designing and interpreting nonclinical studies that predict human risk. This blog provides targeted multiple-choice questions with answers focused on mechanistic understanding, study design, regulatory expectations, and translational challenges. Use these MCQs to deepen your knowledge, prepare for exams, and apply safety pharmacology principles in screening and drug-development contexts.

Q1. What is the primary objective of safety pharmacology studies?

• To determine the maximal efficacious dose in humans
• To identify potential undesirable pharmacodynamic effects on vital organ systems
• To establish long-term carcinogenic risk
• To replace toxicology studies in regulatory submissions

Correct Answer: To identify potential undesirable pharmacodynamic effects on vital organ systems

Q2. Which organ systems constitute the ICH S7A “core battery” for safety pharmacology?

• Hepatic, renal and hematopoietic systems
• Cardiovascular, respiratory and central nervous systems
• Gastrointestinal, endocrine and immune systems
• Musculoskeletal, integumentary and sensory systems

Correct Answer: Cardiovascular, respiratory and central nervous systems

Q3. The in vitro hERG assay primarily evaluates a compound’s potential to:

• Induce hepatic enzyme induction
• Block a cardiac potassium channel linked to QT prolongation
• Cause respiratory depression through opioid receptors
• Cross the blood–brain barrier

Correct Answer: Block a cardiac potassium channel linked to QT prolongation

Q4. Which nonclinical study approach provides continuous measurement of ECG, arterial pressure and activity in conscious animals?

• Acute terminal anesthesia-based recording
• Telemetry in freely moving animals
• In vitro tissue bath studies
• Microdialysis sampling under restraint

Correct Answer: Telemetry in freely moving animals

Q5. According to ICH guidance, which document specifically addresses nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation)?

• ICH S1
• ICH S7A
• ICH S7B
• ICH M3

Correct Answer: ICH S7B

Q6. The margin of safety (MOS) commonly used in safety pharmacology is best described as:

• The therapeutic index calculated from ED50 and LD50 in rodents
• The ratio of nonclinical NOAEL exposure to anticipated clinical exposure
• The absolute difference between Cmax and Tmax
• The ratio of hospital adverse events to clinical trial size

Correct Answer: The ratio of nonclinical NOAEL exposure to anticipated clinical exposure

Q7. Which of the following is a primary advantage of using conscious telemetry models over anesthetized preparations for cardiovascular safety assessment?

• Lower cost and faster setup time
• Ability to measure molecular biomarkers directly
• Physiological responses unaffected by anesthetic agents and stress from restraint
• Elimination of the need for drug exposure measurements

Correct Answer: Physiological responses unaffected by anesthetic agents and stress from restraint

Q8. Secondary pharmacology studies are primarily designed to:

• Confirm efficacy in target disease models
• Investigate off-target interactions that may cause adverse effects
• Replace core battery safety tests
• Evaluate chronic toxicity over 2 years

Correct Answer: Investigate off-target interactions that may cause adverse effects

Q9. Which cardiac biomarker is most specific for myocardial injury and often used in translational safety assessments?

• Creatine kinase-MB (CK-MB)
• Troponin I
• Aspartate aminotransferase (AST)
• C-reactive protein (CRP)

Correct Answer: Troponin I

Q10. Which heart rate correction formula is generally preferred in regulatory QT assessments because it reduces heart-rate dependency?

• Bazett’s formula (QTcB)
• Fridericia’s formula (QTcF)
• Linear correction by body weight
• No correction is preferred

Correct Answer: Fridericia’s formula (QTcF)

Q11. In the context of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, what is the principal improvement over single hERG testing?

• Replacement of in vivo telemetry
• Integration of multiple ion-channel data with in silico human ventricular models
• Exclusive use of non-mammalian species
• Only measuring QT interval in rodents

Correct Answer: Integration of multiple ion-channel data with in silico human ventricular models

Q12. For respiratory safety pharmacology, which technique provides noninvasive measurement of tidal volume and respiratory rate in conscious small animals?

• Plethysmography
• Terminal blood gas under anesthesia
• Bronchoalveolar lavage cytology
• Pulmonary histopathology

Correct Answer: Plethysmography

Q13. Which factor is most important when selecting a species for nonclinical safety pharmacology studies?

• Availability of historical control data only
• Pharmacological relevance and sensitivity of the species to the drug target
• Lowest cost per animal
• Ease of housing and handling

Correct Answer: Pharmacological relevance and sensitivity of the species to the drug target

Q14. Which type of safety pharmacology study is typically expected before first-in-human dosing?

• Long-term carcinogenicity studies
• Core battery safety pharmacology studies and hERG assessment
• Two-year chronic toxicity studies
• Clinical Phase II efficacy trials

Correct Answer: Core battery safety pharmacology studies and hERG assessment

Q15. In safety pharmacology study design, why is it important to collect plasma drug concentration (PK) data alongside functional endpoints?

• To replace the need for dose-ranging studies
• To correlate exposure with pharmacodynamic effects and define exposure-response relationships
• To allow conversion of animal dose to mg/kg human dose directly
• Because regulatory agencies require PK for GLP certification only

Correct Answer: To correlate exposure with pharmacodynamic effects and define exposure-response relationships

Q16. Which method is most appropriate to detect subtle central nervous system (CNS) effects such as changes in motor activity or sensorimotor function in rodents?

• Irwin neurobehavioral observational battery
• hERG channel current recording
• Whole-body plethysmography
• Telemetry blood pressure measurement

Correct Answer: Irwin neurobehavioral observational battery

Q17. Which statement about GLP (Good Laboratory Practice) and safety pharmacology is most accurate?

• All mechanistic in vitro assays must always be performed under GLP
• Core battery in vivo safety pharmacology studies are generally expected to comply with GLP
• GLP compliance is irrelevant for studies intended only for exploratory research
• GLP prevents any need for rigorous study design or validation

Correct Answer: Core battery in vivo safety pharmacology studies are generally expected to comply with GLP

Q18. Which combination of endpoints is most commonly measured in a cardiovascular telemetry study?

• Blood glucose, liver enzymes, and body weight
• ECG, arterial blood pressure, and heart rate
• Pulmonary function, tidal volume, and blood gases
• Behavioral scoring, EEG, and nociception thresholds

Correct Answer: ECG, arterial blood pressure, and heart rate

Q19. When a compound blocks hERG channels in vitro at concentrations close to anticipated therapeutic plasma levels, the best next step is:

• Immediately discontinue development without further evaluation
• Conduct integrated in vivo cardiovascular studies and additional ion-channel profiling to assess translational risk
• Skip nonclinical studies and proceed to human trials with monitoring
• Reduce dose in animal studies but avoid further cardiac testing

Correct Answer: Conduct integrated in vivo cardiovascular studies and additional ion-channel profiling to assess translational risk

Q20. Pharmacokinetic/pharmacodynamic (PK/PD) modeling in safety pharmacology is mainly used to:

• Predict long-term carcinogenic risk from acute exposures
• Relate plasma concentration to the magnitude and time course of physiological effects
• Replace the need for any in vivo testing
• Determine the chemical structure–activity relationship

Correct Answer: Relate plasma concentration to the magnitude and time course of physiological effects

Download